Ipratropium Bromide And Albuterol Sulfate Solution
Product Images NDC 50090-1669

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Ipratropium Bromide And Albuterol Sulfate (NDC 50090-1669). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

B5387e98-figure-01 (B5387e98 Figure 01)

Chemical structure of Ipratropium Bromide depicted as a molecular diagram including functional groups and sulfate ions.*

FDA Label Image

B5387e98-figure-02 (B5387e98 Figure 02)

Chemical structure diagram of Ipratropium Bromide monohydrate, showing the molecular arrangement of atoms and bonds including a quaternary ammonium group and a bicyclic structure.*

FDA Label Image

B5387e98-figure-03 (B5387e98 Figure 03)

A line graph depicting respiratory volume (liters) over time (hours) after dosing for three treatments: Albuterol, Ipratropium, and Ipratropium Bromide with Albuterol Sulfate inhalation. The graph shows changes in lung volume for each treatment up to 8 hours after dosing.*

FDA Label Image

B5387e98-figure-04 (B5387e98 Figure 04)

A data table listing adverse events occurring in 1% or more of patients in one or more treatment groups, showing the highest percentage in the combination treatment group for Ipratropium Bromide and Albuterol Sulfate. The table compares body system adverse events for Albuterol, Ipratropium, and their combination, including categories such as Body as a Whole, Digestive, Musculo-Skeletal, Respiratory, and Urogenital with corresponding event counts and percentages.*

FDA Label Image

B5387e98-figure-05 (B5387e98 Figure 05)

An instructional diagram showing the preparation of a respiratory inhalation solution. The image depicts a vial labeled with a drug name being inserted into a small chamber or nebulizer device. A user's hand is shown handling the nebulizer mouthpiece.*

FDA Label Image

B5387e98-figure-06 (B5387e98 Figure 06)

An instructional diagram depicting a hand holding a respiratory inhalation device, with a close-up showing the proper insertion of a cap or attachment onto the mouthpiece. The image appears to guide the assembly or preparation of an inhalation solution device for administration.*

FDA Label Image

B5387e98-figure-07 (B5387e98 Figure 07)

An instructional illustration showing a person administering Ipratropium Bromide and Albuterol Sulfate respiratory solution using a nebulizer. The image depicts the technique of holding the nebulizer mouthpiece to the mouth during inhalation.*

FDA Label Image

B5387e98-figure-08 (B5387e98 Figure 08)

An instructional illustration showing the use of a respiratory inhalation device. The diagram depicts a person holding an inhaler with a mouthpiece and a spacer device, positioning it near their mouth for administration of medication.*

FDA Label Image

Label Image (Lbl500901669)

The label for Ipratropium Bromide and Albuterol Sulfate Inhalation Solution, 0.5 mg/3 mL, from A-S Medication Solutions. It includes dosage and storage instructions, and indicates the product is supplied as 30 sterile unit-dose vials (30 kits) with five 3 mL vials per kit. The label displays the NDC 50090-1669-0 and manufacturing information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.